Sectors
BBIO
BridgeBio Pharma, Inc.
82.40
1 x 82.35
1 x 82.44
bid
ask
-
0.05
0.06%
12:27 PM
timesize
| Ytd | 7.73% | |
| 1y | 80.03% |
81.02
day range
82.86
42.09
52 week range
93.42
| Open | 82.47 | Prev Close | 82.45 | Low | 81.02 | High | 82.86 | Mkt Cap | 16.15B |
| Vol | 393.81K | Avg Vol | 3.67M | EPS | -3.74 | P/E | -22.05 | Forward P/E | 153.73 |
| Beta | 0.95 | Short Ratio | 5.83 | Inst. Own | 103.15% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-04 | 50-d Avg | 71.50 | 200-d Avg | 70.24 | 1yr Est | 104.25 |
| Income Statement | |||
| Total Revenue | 194.52M | ||
| Revenues (USD) | 194.52M | ||
| Cost of Revenue | 9.94M | ||
| Gross Profit | 184.58M | ||
| Operating Expenses | 290.53M | ||
| Research and Development Expense | 126.64M | ||
| Selling, General and Administrative Expense | 163.90M | ||
| Operating Income | -105.96M | ||
| Interest Expense | 12.94M | ||
| Net Income | -164.04M | ||
| Net Income Common Stock | -164.04M | ||
| Net Income Common Stock (USD) | -164.04M | ||
| Consolidated Income | -166.55M | ||
| Net Income to Non-Controlling Interests | -2.51M | ||
| Earnings per Basic Share | -0.84 | ||
| Earnings per Basic Share (USD) | -0.84 | ||
| Earnings per Diluted Share | -0.84 | ||
| Earning Before Interest & Taxes (EBIT) | -151.10M | ||
| Earning Before Interest & Taxes (USD) | -151.10M | ||
| Weighted Average Shares | 194.79M | ||
| Weighted Average Shares Diluted | 194.79M | ||
| Balance Sheet | |||
| Cash and Equivalents | 879.89M | ||
| Cash and Equivalents (USD) | 879.89M | ||
| Investments | 121.82M | ||
| Investments Current | 60.30M | ||
| Investments Non-Current | 61.53M | ||
| Trade and Non-Trade Receivables | 205.23M | ||
| Current Assets | 1.24B | ||
| Property, Plant & Equipment Net | 22.17M | ||
| Total Assets | 1.37B | ||
| Debt Current | 551.92M | ||
| Total Debt | 2.49B | ||
| Current Liabilities | 816.37M | ||
| Debt Non-Current | 1.94B | ||
| Total Liabilities | 3.64B | ||
| Accumulated Retained Earnings (Deficit) | -3.99B | ||
| Accumulated Other Comprehensive Income | -8.00K | ||
| Shareholders Equity | -2.28B | ||
| Shareholders Equity (USD) | -2.28B | ||
| Assets Non-Current | 129.68M | ||
| Total Debt (USD) | 2.49B | ||
| Deferred Revenue | 17.89M | ||
| Goodwill and Intangible Assets | 27.36M | ||
| Inventory | 32.98M | ||
| Liabilities Non-Current | 2.82B | ||
| Trade and Non-Trade Payables | 29.06M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 2.65M | ||
| Net Cash Flow from Financing | 549.89M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 309.88M | ||
| Capital Expenditure | -69.00K | ||
| Issuance (Purchase) of Equity Shares | -81.11M | ||
| Issuance (Repayment) of Debt Securities | 619.70M | ||
| Net Cash Flow from Investing | -42.73M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -42.67M | ||
| Net Cash Flow from Operations | -197.28M | ||
| Share Based Compensation | 33.24M | ||